ClinicalTrials.gg
RecruitingNCT06238908Updated Feb 21, 2025

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

An Early Phase 1 interventional study of NGGT003 in Hemophilia A, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China — 11 open to participants now, 12 under way, none of them phase 3. Hemophilia A · Institute of Hematology & Blood Diseases Hospital, China.

Started
2024
with 1 other
Phase 1
3 of 13
3 open now
Primary completion
2026-01
later than 3 of 11 live
Registered
9th of 13
by date

Among the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 2 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 3 of the 11 other live ones, and was the 9th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

11 of the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT003 in hemophilia A patients. NGGT003 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human FVIII gene B domain deletion mutant (hFVIII BDD), and expresses human FVIII protein in the liver through intravenous injection.

Read the detailed description

Hemophilia A (HA) is an X-linked recessive genetic disease caused by mutations in the FVIII gene on the X chromosome, leading to abnormal coagulation function. In the male population, the incidence rate of hemophilia A was about 1/5000, and female patients with hemophilia A were extremely rare. Type A hemophilia patients mainly exhibit a tendency for bleeding, with a wide range of bleeding sites and frequent recurrence, which can form hematoma and joint deformation. This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of a single intravenous infusion of NGGT003 in hemophilia A patients. 4-6 subjects will be enrolled and divided into 3 groups according to the principle of dose escalation, respectively administered intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg). All subjects will undergo 52 weeks of treatment observation and further 260 weeks of long-term follow-up.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form;
  2. Male, age ≥18 years old;
  3. Diagnosed with hemophilia A according to the "Guidelines for Diagnosis and Treatment of Hemophilia A (2022 Edition)", and the endogenous FVIII activity level was \<1 IU/dL (\<1%);
  4. The exposure days (EDs) of treatment with any recombinant or plasma-derived FVIII product were ≥150 days;
  5. Anti-AAV neutralizing antibody titer ≤1:5, binding antibody titer ≤1:100;
  6. Bleeding events and/or FVIII product injections have occurred within 12 weeks before screening;
  7. No history of allergy to FVIII products;
  8. FVIII inhibitor titer﹤0.6BU/mL;
  9. Commitment to use other drugs during the study requires the consent of the investigator;
  10. Willing and able to comply with study procedures and requirements;
  11. Willing to use effective methods within 52 weeks after administration.

Exclusion criteria

Exclusion Criteria:

  1. Positive for surface antigen, , (HIV),syphilis test;
  2. abnormalities in liver function test: (ALT) >1.5 × (ULN) and/or aspartate aminotransferase (AST) >1.5× ULN;TBil)>1.5×ULN;Serum creatinine (Scr) >1.5×ULN; \<110g/L, \<10e9/L;
  3. History of being positive for FVIII inhibitors;
  4. Have other bleeding factors except hemophilia;
  5. Plan major surgery within 52 weeks;
  6. Have to , including but not limited to allergy to glucocorticoids, epilepsy, new unhealed fractures, in trauma repair period, uncontrolled infection, severe osteoporosis, etc, which assessed and determined by the investigators;
  7. History of allergy to human albumin;
  8. Have serious diseases or active infections in cardiovascular, respiratory, digestive tract, endocrine, renal, blood, nervous, mental and other systems before screening;
  9. With hepatitis, cirrhosis, liver cancer or other major liver diseases;
  10. History of malignant tumors;
  11. Abnormal and clinical significant vital signs, physical examination, laboratory examination or other related examination results during the screen, which are not suitable for trial according to the investigator;
  12. Previous gene therapy treatment;
  13. Participation in any other clinical trial before the screening and have taken medication within four weeks or five half-lives of the study drug;
  14. Any other condition that may not be appropriate for the study in the opinion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Experimental

    3 doses of NGGT003 will be administered according to the principle of dose escalation

    Drug: NGGT003

Interventions

  • DrugNGGT003

    Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs) and serious adverse events (SAEs)

    Incidence of AE and SAE, as assessed by physical examinations, clinical laboratory parameters and adverse event reporting

    Time frame: 52 weeks

  2. Changes in annualized bleeding rate (ABR)

    Changes in annualized bleeding rate (ABR) from baseline to 52 weeks.

    Time frame: 52 weeks

Secondary outcomes

  1. FVIII activity levels

    Change in FVIII activity levels from baseline to week 52.

    Time frame: 52 weeks

  2. FVIII protein product infusions

    Calculate the number and volume of FVIII protein product infusions from baseline to week 52.

    Time frame: 52 weeks

  3. Target joints

    Changes the numbers of target joints from baseline to week 52.

    Time frame: 52 weeks

  4. HA-QOL scores

    Change in HA-QOL scores from baseline to 52 weeks.

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2026, 24 months after the start.

Of 46 phase 1 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 26. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 2, 2024
StartActual
Jan 17, 2024
Primary completionEst.
Jan 31, 2026
CompletionEst.
Jan 31, 2030
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238908
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Jan 17, 2024
Primary completion
Jan 31, 2026 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Feb 21, 2025

Study contacts

Wei Liu, MD
Contact
liuwei1@ihcams.ac.cn
+862223909240
Lei Zhang, MD
Contact
zhanglei1@ihcams.ac.cn
+862223909240
Lei Zhang, MD
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion